Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages

Key Points

• Analysts hold a moderately bullish view of Vor Biopharma, with five buy ratings, two strong-buy ratings, and three holds. The average 12-month price target is $41.71, compared with the stock’s opening price of $18.52.
• Institutional investors and hedge funds own 97.29% of VOR, with several firms recently increasing positions or initiating new stakes.
• Vor Biopharma reported a quarterly loss of $0.80 per share, missing the consensus estimate of $0.69, while analysts expect a full-year loss of approximately $2.56 per share.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $41.71.

VOR has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, September 14th. Wall Street Zen raised shares of Vor Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, Wedbush increased their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VOR. Bank of America Corp DE raised its position in Vor Biopharma by 28,408.1% in the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock valued at $2,014,000 after buying an additional 112,496 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Vor Biopharma in the 1st quarter valued at approximately $2,298,000. Wellington Management Group LLP acquired a new position in Vor Biopharma during the 2nd quarter worth approximately $499,000. Frazier Life Sciences Management L.P. acquired a new position in Vor Biopharma during the 4th quarter worth approximately $33,275,000. Finally, Braidwell LP grew its stake in shares of Vor Biopharma by 22.8% during the 2nd quarter. Braidwell LP now owns 573,104 shares of the company's stock worth $10,551,000 after acquiring an additional 106,330 shares in the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $18.52 on Monday. The company's 50 day moving average price is $22.14 and its two-hundred day moving average price is $17.85. Vor Biopharma has a 52 week low of $6.50 and a 52 week high of $49.95.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). On average, analysts predict that Vor Biopharma will post -2.56 earnings per share for the current year.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor's lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.